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Summary Few studies have examined the prevalence of onychomycosis among diabetic patients.
Given the morbidity linked to onychomycosis, and the ever-growing size of the diabetic
population, a better recognition of this nail infection is welcome. To revisit the relative
prevalence of dermatophyte, yeast and non-dermatophytic mould onychomycoses in
diabetic adults in a prospective study using combined histomycology and cultures.
Toenail clippings were collected for 3 years in 190 type II diabetic patients (136 men
and 54 women) and from an age- and gender-matched group of non-diabetic subjects.
All sampled nails showed clinical alterations reminiscent of onychomycosis.
Histomycology and cultures were performed on each sample to distinguish
onychomycosis from non-infectious onychodystrophy. Compared to non-diabetic
subjects with nail alterations, diabetics showed a higher proportion of
onychomycosis relative to non-fungal onychodystrophy. Diabetic men suffered more
frequently from onychomycosis and onychodystrophy than diabetic women. When
considering the nature of the fungal pathogens, dermatophytes predominated largely
over yeast and non-dermatophytic moulds, both in diabetic and non-diabetic patients.
Diabetic patients, particularly men, are at increased risk of developing onychomycosis.
The morbidity linked to this disorder, and its impact on the foot status in diabetic
subjects merit to be better appreciated by clinicians.
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Introduction
The endeavoursmade in the past to find a quick, safe and,
in the long run, satisfactory solution to the problem posed
by onychomycosis were not completely successful. Top-
ical and systemic therapeutic regimens exist, but have so
far failed tomeet general wishful thinking. The problem is
more complex in polymedicated patients and in those
showing an increased propensity to develop fungal
infection of the nails.1, 2
The high frequency with which foot disorders occur
in diabetic patients turns it into considerable public
health problem. Nail alterations can be one of the
problems of this condition.3, 4 In the past decade or so
several studies have evaluated the prevalence of ony-
chomycosis in these patients.5–16 Overall, clinically
abnormal nails with mycological evidence of fungal
disease have been reported in approximately one-thirds
of diabetics.9 The highest prevalence was reported in
men with type II diabetes.8, 9, 11, 13 The overall risk ratio
of diabetic patients having onychomycosis was estima-
ted as high as 2.77 compared with age- and sex-
matched non-diabetic subjects.9 In some studies, yeast
infections of the nail were found to be more frequent in
diabetic patients.16, 17 However, this propensity was not
observed in other studies.9
Angiopathy, retinopathy, neuropathy and increasing
age are considered to represent predisposing factors for
onychomycosis in diabetic patients.6, 8 Impaired sensa-
tion in the foot can mask minor trauma and abrasions
from nail contact with the skin. This situation together
with poor nail grooming, enhance the possibility of
microbial infections contributing to the severity of the
diabetic foot.8, 14 Thus, nail infections represent a risk
factor in the diabetic patients because of possible sequelae.
Correspondence: Gérald E. Piérard, Department of Dermatopathology, CHU
Sart Tilman, B-4000 Liège, Belgium.
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The aim of this work was to revisit the relative
prevalence of dermatophyte, yeast and non-dermato-
phytic mould onychomycoses in type II diabetic patients
and in age- and gender-matched non-diabetic controls
only suffering from nail alterations.
Materials and methods
This prospective and comparative study was performed
on nail clippings collected for 3 years from 190 type II
diabetic outpatients aged from 44 to 57 years. Among
them, there were 136 (71.6%) men and 54 (28.4%)
women. This group of subjects corresponded to con-
secutive diabetic patients consulting a dermatology
division because they complained from an altered aspect
of toenails showing discoloration, thickening and dys-
trophy. None of the patient had received antifungal
therapy for at least the past 6 months. All of them were
treated by oral antidiabetic drugs. No information was
available about the average control level of their
glycaemia. All of them were outpatients who did not
report any major clinical consequence of diabetes. A
control group was formed by non-diabetic age- and
gender-matched subjects presenting similar nail chan-
ges. None of the 380 subjects suffered from skin
disorders known to alter the nail aspect.
The unfixed nail samples were sliced. Some of the slices
were further fragmented and deposited onto Sabouraud
medium (Mycoline, BioMerieux, Marcy I’Etoile, France)
for mycological cultures. Other slices were embedded in
agar for histomycology. After trimming, they were put in
contact with Tween-40 in order to soften the nail
structure. This material was cut with a microtome for
obtaining 6-lm-thick histological sections. They were
stained with the periodic acid-Schiff reagents in order to
reveal fungi inside the nail plate. The diagnosis of
onychomycosis was given when histomycology was
positive, and onychodystrophy was considered when this
evaluation revealed no fungi. The diagnostic criteria in
histomycology have been described in previous stud-
ies.17, 18 In particular finding yeast only was considered
to merely represent colonization. By contrast, yeast and
pseudofilaments were interpreted as a true infection.
Onychomycoses were further identified according to
the nature of the fungus growing at culture. They were
thus classified as dermatophyte, yeast or non-dermato-
phytic mould onychomycoses. When two distinct fungi
were seen microscopically and isolated simultaneously
from a nail sample, mixed fungal infection of the nail
plate was diagnosed. Some onychomycoses remained
unidentified because the culture remained negative.
This condition most probably indicated the presence of a
dead portion of the fungal mycelium in the sampled nail
clipping.
Data were expressed as total numbers and percent-
ages. Differences in nail disorder prevalence between
diabetic and non-diabetic patients were assessed using
the chi-square test and variance analysis. Differences
were considered significant when the P-value was lower
than 0.05.
Results
There were no cases of positive cultures for dermato-
phytes which were negative histologically. By contrast,
it was not exceptional to record yeast and moulds
growing at culture, without showing nail invasion at
histology. This condition corresponding to nail contam-
ination was recorded as onychodystrophy.
Data are presented in Table 1. When pooling all data
irrespective of the gender, the ratio between onycho-
mycoses and non-infectious onychodystrophies reached
1.88 (124 of 66) in diabetic patients, which was twice
the value 0.94 (92 of 98) found in non-diabetic
controls. A similar finding was obtained when consid-
ering each gender group separately. Indeed, the ratio
reached 1.97 (90 of 46) in diabetic men and 1.00 (68 of
68) in non-diabetic men. It reached 1.70 (34 of 20) in
diabetic women and 0.80 (24 of 30) in non-diabetic
women.
The proportion of unidentified onychomycoseswas not
significantly different among the different groups of
subjects. In most of these cases, the fungal hyphae were
irregular in shape and appeared empty at the histological
examination. Among onychomycoses, those caused by
dermatophytes, particularly Trichophyton rubrum, pre-
vailed similarly in all groups of individuals. They repre-
sented 62.7% (64 of 102) of the mycologically identified
Table 1 Numbers and percentages of onychomycoses and ony-
chodystrophies in the two age- and sex-matched groups of 190






Men Women Men Women
Onychodystrophy 46 (33.8) 20 (37.0) 68 (50.0) 30 (55.6)
Onychomycosis
Dermatophyte 51 (37.5) 13 (24.1) 39 (28.7) 10 (18.5)
Yeast 8 (5.9) 5 (9.3) 7 (5.1) 3 (5.5)
Mould 13 (9.6) 4 (7.4) 8 (5.9) 3 (5.5)
Mixed 6 (4.4) 5 (9.2) 3 (2.2) 3 (5.5)
Unidentified 12 (8.8) 7 (13.0) 11 (8.1) 5 (9.3)
Total 136 (100) 54 (100) 136 (100) 54 (100)
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diabetic cases and 64.5% (49 of 76) of the non-diabetic
cases. This proportion was higher (P < 0.05) in men,
either diabetic (68%,51of75) ornon-diabetic (68.4%,39
of 57) than inwomen, either diabetic (48.1%, 13of 27) or
non-diabetic (52.6%, 10 of 19).
The prevalence of yeast onychomycoses was similar
in diabetic patients (12.7%, 13 of 102) and in non-
diabetic subjects (13.2%, 10 of 76). No gender influence
was observed for this type of onychomycosis. Similar
prevalence findings were found for non-dermatophytic
mould onychomycoses. The identified mould genera
encompassed Aspergillus spp., Acremonium spp., Alterna-
ria tennis, Fusarium oxysporum and Scopulariopsis
brevicaulis.
Discussion
In this study, the diagnosis of onychomycosis primarily
relied on histomycology. Any positive culture without
histological clue for fungal infection was not considered
to be sufficient for diagnosing onychomycosis. These
stringent criteria are open for discussion because some
authors may argue that cultural isolation of a mould
from a nail plate with signs of onychodystrophy may
indicate the infection. For sure, our diagnostic proce-
dure reduces the risk of overestimating the prevalence of
onychomycosis, but it may discretely underestimate it.
Clinically abnormal nails with mycological evidence
of fungal disease are not rare in diabetic patients in
whom the prevalence of onychomycosis was reported to
be higher with increasing age and male gender.9, 12
Diabetic men were reported to be about three times as
likely to have onychomycosis as women with diabetes.9
The present study was based for the first time on the
combination of histomycology and cultures for assessing
the nature of abnormal nails present in diabetic
patients. This dual diagnostic method allows to distin-
guish with certainty the cases of fungal contamination
from fungal invasion of the nail apparatus. This aspect
is important to be stressed because the proportion of
false-positive and false-negative data at culture alone is
high in routine clinical practice.17, 18
In diabetic patients, men were 2.5 times more
numerous than women. This gender difference was
present for onychomycoses, but also for fungus-negative
onychodystrophies. This indicates that gender-related
factors affect the nail structure. This situation has never
been reported so far. It may be due to differences in life
style, propensity to microtraumatisms, professional
activities, sport practices, etc.
The comparison between the present diabetic and
non-diabetic groups shows that the proportion of
onychomycoses among all nail alterations is much
increased in diabetics irrespective of the gender. The
increased risk of fungal nail infection was observed for
the three families of pathogenic fungi. These findings
concern a general group of type II diabetic patients who
had no severe clinical manifestations of their metabolic
disease.
Dermatophytes, yeast and non-dermatophytic moulds
can be responsible for onychomycoses.5, 14, 17–23 In a
North American survey in diabetic patients,9 the
organisms involved in onychomycosis were dermato-
phytes (88.2%), non-dermatophytic moulds (9.1%) and
Candida spp. (2.7%). However, other investigators
reported that Candida spp. infections of the nail and
surrounding area might be more prevalent in diabetic
patients.5 The present study does not shows any
increased prevalence of Candida over other fungi in
onychomycoses of diabetic patients. This finding can be
opposed to previous observations made in our laborat-
ory showing that C. albicans grew more easily on
stratum corneum of diabetic patients than on the same
structure of non-diabetic subjects.24 These older data
should now be revisited at the light of the discovery of
the innate immune activity of natural antimicrobial
peptides synthesized in the epidermis and nails.25–27 The
antifungal activity of these peptides have not been
specifically studied in diabetic subjects so far. Any
glycation of these molecules could impair their defence
potential against fungi.
While mild toenail onychomycoses may pose little
problem to diabetic subjects, more severe, neglected
onychomycosis can be a real threat.11 The presence of
the mycotic nail may result in adjacent nail or skin
injury, and provide a reservoir of pathogen fungi,
thereby further increasing the risk of serious sequelae
and spread of infection.8 In particular, high-risk diabetic
patients with compromised lower extremities and severe
neuropathy were reported to be at increased risk of
developing complications from onychomycosis.11 Most
notably, impaired sensation can make many diabetics
less aware of minor abrasions and ulcerations on their
feet that may be caused by trauma, form poor nail
grooming or by the sharp, brittle of infected nails.8
These lesions, in turn, may develop into serious
paronychia, cellulitis or other bacterial infections, and
contribute to the severity of the diabetic foot. Osteomy-
elitis can also result from chronically infected nail bed
with erosion in diabetic patients because of the close
proximity of the nail bed to the underlying bone.11
Thus, there is an important clinical rationale for
identifying and treating diabetic patients with fungal
nail infections.14
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As the population of diabetic subjects keeps growing
in western populations, the clinical and pharmaco-
economical impact of onychomycosis in these individ-
uals will likely increase. The increasing onychomycosis
incidence, the varied epidemiology and the physical and
psychological consequences of the disease emphasize the
need for prompt and effective antifungal treatment in
susceptible patient populations. Data from clinical trials
and postmarketing surveillance suggest that drug
interactions with antidiabetic drugs may not be an
important issue when itraconazole and terbinafine are
administered as antifungals. In contrast, fluconazole has
an interaction with some oral antidiabetic agents.
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